BNP7787-mediated modulation of paclitaxel- and cisplatin-induced aberrant microtubule protein polymerization in vitro

Molecular Cancer Therapeutics

Volumn 9, Issue 9, 2010, Pages 2558-2567

  Parker, Aulma R ^a   Petluru, Pavankumar N ^a   Wu, Meizhen ^a,b   Zhao, Min ^a   Kochat, Harry ^a   Hausheer, Frederick H ^a  

^a BioNumerik Pharmaceuticals Inc   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DIMESNA; DOCETAXEL; MICROTUBULE PROTEIN; OXALIPLATIN; PACLITAXEL;

ADVANCED CANCER; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EXPOSURE; DRUG MECHANISM; DRUG PROTEIN BINDING; HUMAN; IN VIVO STUDY; INOPERABLE CANCER; LUNG ADENOCARCINOMA; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROPROTECTION; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN POLYMERIZATION; THERAPY DELAY; TIME; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; CATTLE; CISPLATIN; DRUG INTERACTIONS; MESNA; MICROTUBULE PROTEINS; MICROTUBULES; PACLITAXEL; POLYMERIZATION;

EID: 77956603734     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0300     Document Type: Article

References (50)

1. Reed E. Cisplatin and analogs. In: Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy: principles and practice. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2001, p. 447-65.
2. Rowinsky EK, Onetto N, Canetta RM, Arbuck SG. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol 1992;19:646-62.
3. Cavaletti G, Marzorati L, Bogliun G, et al. Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer 1992;69:203-7.
4. Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC. Neurotoxicity of Taxol. J Natl Cancer Inst Monogr 1993;15:107-15.
5. van Gerven JM, Moll JW, van den Bent MJ, et al. Paclitaxel (Taxol) induces cumulativemild neurotoxicity. Eur J Cancer 1994;30A: 1074-7.
6. Cavaletti G, Bogliun G, Marzorati L, et al. Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer 1995;75:1141-50.
7. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule- stabilizing agents. J Clin Oncol 2006;24:1633-42.
8. Rowinsky E, Donehower R. Antimicrotubule agents. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven; 1997, p. 467-83.
9. Cavaletti G, Cascinu S, Venturino P, Tedeschi M, Tredici G. Neuroprotectant drugs in cisplatin neurotoxicity. Anticancer Res 1996;16:3149-59.
10. Cavaletti G, Zanna C. Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. Eur J Cancer 2002;38:1832-7.
11. Hausheer FH, Kochat H, Parker AR, et al. New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent. Cancer Chemother Pharmacol 2003;52 Suppl 1:S3-15.
12. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 2008;44:1507-15.
13. Loven D, Levavi H, Sabach G, et al. Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel. Eur J Cancer Care 2009;18:78-83.
14. Reed E. Cisplatin. In: Pinedo HM, Longo DL, Chabner BA, editors. Cancer chemotherapy and biological response modifiers. Annual 18. Elsevier; 1999, p. 144-51.
15. Lipton RB, Apfel SC, Dutcher JP, et al. Taxol produces a predominantly sensory neuropathy. Neurology 1989;39:368-73.
16. Postma TJ, Vermorken JB, Liefting AJ, Pinedo HM, Heimans JJ. Paclitaxel-induced neuropathy. Ann Oncol 1995;6:489-94.
17. Roytta M, Raine CS. Taxol-induced neuropathy: further ultrastructural studies of nerve fibre changes in situ. J Neurocytol 1985;14:157-75.
18. Sahenk Z, Barohn R, New P, Mendell JR. Taxol neuropathy. Electrodiagnostic and sural nerve biopsy findings. Arch Neurol 1994;51:726-9.
19. McLean G. Neurotoxicity and axonal transport. Trends Pharmacol Sci 1984:243-6.
20. McLean WG. The role of axonal cytoskeleton in diabetic neuropathy. Neurochem Res 1997;22:951-6.
21. Boekelheide K, Arcila ME, Eveleth J. cis-Diamminedichloroplatinum (II) (cisplatin) alters microtubule assembly dynamics. Toxicol Appl Pharmacol 1992;116:146-51.
22. Peyrot V, Briand C, Crevat A, Braguer D, Chauvet-Monges AM, Sari JC. Action of hydrolyzed cisplatin and some analogs on microtubule protein polymerization in vitro. Cancer Treat Rep 1983;67:41-6.
23. Peyrot V, Briand C, Momburg R, Sari JC. In vitro mechanism study of microtubule assembly inhibition by cis-dichlorodiammine-platinum (II). Biochem Pharmacol 1986;35:371-5.
24. Tulub AA, Stefanov VE. Cisplatin stops tubulin assembly into microtubules. A new insight into the mechanism of antitumor activity of platinum complexes. Int J Biol Macromol 2001;28:191-8.
25. Canta A, Chiorazzi A, Cavaletti G. Tubulin: a target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system. Curr Med Chem 2009;16:1315-24.
26. Rao S, Horwitz SB, Ringel I. Direct photoaffinity labeling of tubulin with taxol. J Natl Cancer Inst 1992;84:785-8.
27. Rao S, Krauss NE, Heerding JM, et al. 3′-(p-Azidobenzamido)taxol photolabels the N-terminal 31 amino acids of β-tubulin. J Biol Chem 1994;269:3132-4.
28. Rao S, Orr GA, Chaudhary AG, Kingston DG, Horwitz SB. Characterization of the taxol binding site on the microtubule. 2-(m-Azidobenzoyl) taxol photolabels a peptide (amino acids 217-231) of β-tubulin. J Biol Chem 1995;270:20235-8.
29. Snyder JP, Nettles JH, Cornett B, Downing KH, Nogales E. The binding conformation of Taxol in β-tubulin: a model based on electron crystallographic density. Proc Natl Acad Sci U S A 2001;98:5312-6.
30. Schiff PB, Horwitz SB. Taxol assembles tubulin in the absence of exogenous guanosine 5′-triphosphate or microtubule-associated proteins. Biochemistry 1981;20:3247-52.
31. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665-7.
32. Horwitz SB, Lothstein L, Manfredi JJ, et al. Taxol: mechanisms of action and resistance. Ann N Y Acad Sci 1986;466:733-44.
33. Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 1999;99:2467-98.
34. Roberts JJ, Thomson AJ. The mechanism of action of antitumor platinum compounds. Prog Nucleic Acid Res Mol Biol 1979;22:71-133.
35. Banks P, Till R. A correlation between the effects of anti-mitotic drugs on microtubule assembly in vitro and the inhibition of axonal transport in noradrenergic neurones. J Physiol 1975;252:283-94.
36. Hausheer F, Bain S, Perry M, et al. Comprehensive meta-analysis of survival outcomes from two randomized multicenter trials in first-line advanced non-small cell lung cancers in patients treated with the novel investigational antitumor-enhancing and chemoprotective agent Tavocept. Eur J Clin Med Oncol 2010;2:1-13.
37. Hausheer FH, Kanter P, Cao S, et al. Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents. Semin Oncol 1998;25:584-99.
38. Verschraagen M, Boven E, Ruijter R, et al. Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites. Clin Pharmacol Ther 2003;74:157-69.
39. Verschraagen M, Boven E, Zegers I, Hausheer FH, van der Vijgh WJ. Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites: a case report. Cancer Chemother Pharmacol 2003;51:525-9.
40. Pendyala L, Schwartz G, Smith P, Zdanowicz J, Murphy M, Hausheer F. Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy. Cancer Chemother Pharmacol 2003;51:376-84.
41. Hausheer FH, Kochat H, Zhao M, Seetharamulu P, Huang Q, Berghorn E. BNP7787, a novel neuroprotective agent in taxane and platinum regimens, does not interfere with antitumor activity [abstract 1990]. Proc Amer Assoc Cancer Res 2001;42:370.
42. Gaskin F, Cantor CR, Shelanski ML. Biochemical studies on the in vitro assembly and disassembly of microtubules. Ann N Y Acad Sci 1975;253:133-46.
43. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
44. Markman M. Chemotherapy-induced peripheral neuropathy: an increasing concern for oncologists. Curr Oncol Rep 2005;7:159-60.
45. Markman M. Chemotherapy-induced peripheral neuropathy: underreported and underappreciated. Curr Pain Headache Rep 2006;10:275-8.
46. Boven E, Verschraagen M, Hulscher TM, et al. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts. Eur J Cancer 2002;38:1148-56.
47. Boven E, Westerman M, van Groeningen CJ, et al. Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule. Br J Cancer 2005;92:1636-43.
48. Shanmugarajah D, Ding D, Huang Q, et al. Analysis of BNP7787 thiol-disulfide exchange reactions in phosphate buffer and human plasma using microscale electrochemical high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877:857-66.
49. Hausheer FH, Shanmugarajah D, Leverett BD, et al. Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of γ-glutamyl transpeptidase. Cancer Chemother Pharmacol 2010;65:941-51.
50. Hausheer FH, Parker AR, Petluru PN, et al. Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of human aminopeptidase N. Cancer Chemother Pharmacol 2010, in press.